行情

VYNT

VYNT

Vyant Bio Inc
NASDAQ

实时行情|Nasdaq Last Sale

2.040
-0.010
-0.49%
休市 16:00 11/26 EST
开盘
2.010
昨收
2.050
最高
2.040
最低
1.960
成交量
4.34万
成交额
--
52周最高
17.50
52周最低
1.960
市值
5,913.88万
市盈率(TTM)
-0.5567
分时
5日
1月
3月
1年
5年
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 1天前
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest...
Investor Brand Network · 11/15 19:41
70 Biggest Movers From Friday
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4 sales guidance above estimates.
Benzinga · 11/15 09:40
Vyant Bio EPS 在线,未实现收入
Vyant Bio (NASDAQ:VYNT): Q3 GAAP EPS of -$0.15 in-line. Revenue of $1.5M (+354.5% Y/Y) misses by $0.69M. Press Release
Seekingalpha · 11/11 21:20
Vyant Bio Q3 EPS $(0.15), Inline, Sales $1.51M Miss $2.19M Estimate
Vyant Bio (NASDAQ:VYNT) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. The company reported quarterly sales of $1.51 million which missed the analyst consensus estimate of $2.19
Benzinga · 11/11 21:03
BRIEF-Vyant Bio Reports Third Quarter 2021 Results And Provides Strategic Business Updates
reuters.com · 11/11 21:02
Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates
Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio’s R&D programs targeting the identification of novel therapeuticsEntered into two new first phase feasibility programs with leading biopharma companies to dem...
GlobeNewswire · 11/11 21:00
-- Earnings Flash (VYNT) VYANT BIO Reports Q3 Revenue $1.51M
MT Newswires · 11/11 16:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解VYNT最新的财务预测,通过VYNT每股收益,每股净资产,每股现金流等数据分析Vyant Bio Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
0.00%买入
100.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测VYNT价格均价为3.000,最高价位3.000,最低价为3.000。
最高3.000
均价3.000
最低3.000
现价2.040
EPS
实际EPS
预期EPS
-1.85-1.39-0.92-0.46
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 40
机构持股: 539.79万
持股比例: 18.62%
总股本: 2,898.96万
类型机构数股数
增持
6
4.06万
建仓
1
10.92万
减持
4
1.21万
平仓
7
12.69万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.30%
制药与医学研究
+0.44%
高管信息
Chairman/Director
John Fletcher
President/Chief Executive Officer/Director
John Roberts
Chief Financial Officer
Andrew LaFrence
Corporate Executive
Ralf Brandt
Senior Vice President
Barb Jones
Other/Director
Yung-Ping Yeh
Director
Marcus Boehm
Director
Paul Hansen
Director
Joanna Horobin
Independent Director
Geoffrey Harris
Independent Director
Howard McLeod
暂无数据
VYNT 简况
Vyant Bio Inc(原名:Cancer Genetics Inc)是一家生物技术药物发现公司。该公司致力于通过电脑模拟、体外和体内方法检测分子疗法并做出决策。它提供了AnalytiX平台,该平台通过分析功能数据,通过排序方法确定候选药物、靶标和生物标记物。它的microOrgan技术使用从诱导多能干细胞(iPSC)改造而来的功能性微组织来促进基于人类的药物发现。它拥有两家子公司,vivoPharm Pty Ltd(vivoPharm)和StemoniX Inc(StemoniX)。它的子公司vivoPharm提供早期临床前测试系统,以支持制药行业、生物技术公司和学术研究中心所重视的早期临床诊断产品。StemoniX开发和制造用于药物发现和开发的人诱导多能干(iPS)细胞源性神经和心脏筛查平台。

微牛提供Vyant Bio Inc(NASDAQ-VYNT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的VYNT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易VYNT股票基本功能。